WO2019164010A1 - Agent antitumoral contre le cancer de la vessie et méthode de traitement du cancer de la vessie - Google Patents
Agent antitumoral contre le cancer de la vessie et méthode de traitement du cancer de la vessie Download PDFInfo
- Publication number
- WO2019164010A1 WO2019164010A1 PCT/JP2019/007242 JP2019007242W WO2019164010A1 WO 2019164010 A1 WO2019164010 A1 WO 2019164010A1 JP 2019007242 W JP2019007242 W JP 2019007242W WO 2019164010 A1 WO2019164010 A1 WO 2019164010A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bladder cancer
- antitumor agent
- compound
- salt
- prodrug
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the effect of treatment was determined according to the following criteria.
- the evaluation object was confirmed by image diagnosis by MRI (nuclear magnetic resonance imaging), and judged according to the following criteria.
- CR Complete Response
- PR Partial Response
- SD stable disease
- PD progressive disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Le problème abordé par la présente invention est de fournir un agent antitumoral contre le cancer de la vessie qui présente un effet contre le cancer de la vessie, et une méthode de traitement du cancer de la vessie. L'invention concerne un agent antitumoral contre le cancer de la vessie qui contient de la 1-(2-désoxy-2-fluoro-4-thio-β-D-arabinofuranosyl)cytosine ou un sel ou un promédicament de celle-ci.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862635269P | 2018-02-26 | 2018-02-26 | |
US62/635,269 | 2018-02-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019164010A1 true WO2019164010A1 (fr) | 2019-08-29 |
Family
ID=67688200
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2019/007242 WO2019164010A1 (fr) | 2018-02-26 | 2019-02-26 | Agent antitumoral contre le cancer de la vessie et méthode de traitement du cancer de la vessie |
Country Status (2)
Country | Link |
---|---|
TW (1) | TW202000207A (fr) |
WO (1) | WO2019164010A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023008511A1 (fr) | 2021-07-29 | 2023-02-02 | 富士フイルム株式会社 | Composition pharmaceutique et agent antitumoral pour des tumeurs présentant au moins une fonction bap1 ou pbrm1 altérée |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997038001A1 (fr) * | 1996-04-09 | 1997-10-16 | Yamasa Corporation | 1-(2-DESOXY-2-FLUORO-4-THIO-β-D-ARABINOFURANOSYL)CYTOSINES |
-
2019
- 2019-02-26 TW TW108106499A patent/TW202000207A/zh unknown
- 2019-02-26 WO PCT/JP2019/007242 patent/WO2019164010A1/fr active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997038001A1 (fr) * | 1996-04-09 | 1997-10-16 | Yamasa Corporation | 1-(2-DESOXY-2-FLUORO-4-THIO-β-D-ARABINOFURANOSYL)CYTOSINES |
Non-Patent Citations (2)
Title |
---|
MIURA, SHINJI ET AL.: "Antitumor activity of a novel orally effective nucleoside , 1-(2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranosyl)cytosine", CANCER LETTERS, vol. 129, 1998, pages 103 - 110, XP055213439, doi:10.1016/S0304-3835(98)00089-5 * |
MIURA, SHINJI ET AL.: "Comparison of 1-(2-deoxy-2-fluoro-4-thio- beta -D-arabinofuranosyl)cytosine with gemcitabine in its antitumor activity", CANCER LETTERS, vol. 144, 1999, pages 177 - 182, XP055213437, doi:10.1016/S0304-3835(99)00221-9 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023008511A1 (fr) | 2021-07-29 | 2023-02-02 | 富士フイルム株式会社 | Composition pharmaceutique et agent antitumoral pour des tumeurs présentant au moins une fonction bap1 ou pbrm1 altérée |
KR20240028451A (ko) | 2021-07-29 | 2024-03-05 | 후지필름 가부시키가이샤 | Bap1 및 pbrm1 중 적어도 하나의 기능 저하를 갖는 종양에 대한 의약 조성물 및 항종양제 |
Also Published As
Publication number | Publication date |
---|---|
TW202000207A (zh) | 2020-01-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101589026B (zh) | 治疗脑神经胶质瘤的方法 | |
JP2024063227A (ja) | 肥満細胞症の治療のための併用療法 | |
US11229602B2 (en) | Formulations for treating bladder cancer | |
KR102377742B1 (ko) | 암치료약 | |
WO2021063332A1 (fr) | Utilisation d'un inhibiteur d'ezh2 en association avec un inhibiteur de cdk4/6 dans la préparation d'un médicament pour le traitement d'une tumeur | |
US11141421B2 (en) | Antitumor agent for biliary tract cancer and method for treating biliary tract cancer | |
EP3429582B1 (fr) | Polythérapie pour traiter les maladies prolifératives | |
WO2023092943A1 (fr) | Utilisation de chlorhydrate de dronédarone en association avec du 5-fluorouracile dans la préparation d'un médicament antitumoral | |
WO2015172712A1 (fr) | Composition pharmaceutique pour injection avec effet synergique de la vitamine c et des médicaments antitumoraux | |
JP2003523944A (ja) | P−糖タンパク質修飾物質を用いる抗ウィルス療法 | |
WO2018043530A1 (fr) | Agent antitumoral, activateur d'effet antitumoral et kit anti-tumoral | |
WO2019176984A1 (fr) | Agent anti-tumoral, potentialisateur d'effet anti-tumoral et kit anti-tumoral | |
WO2019164010A1 (fr) | Agent antitumoral contre le cancer de la vessie et méthode de traitement du cancer de la vessie | |
US10953004B2 (en) | Combination therapy for proliferative diseases | |
WO2019242688A1 (fr) | Combinaison d'acide 3-hydroxyaminobenzoïque et de sorafénib pour le traitement de cancers | |
TWI835050B (zh) | 一種吡啶并[1,2-a]嘧啶酮類似物的應用 | |
WO2019146129A1 (fr) | Composition pharmaceutique contre une tumeur présentant une mutation de l'isocitrate déshydrogénase, agent antitumoral et utilisation associée | |
US7863255B2 (en) | Methods of administering antitumor agent comprising deoxycytidine derivative | |
WO2022199656A1 (fr) | Combinaison pharmaceutique, kit la contenant et son utilisation | |
WO2019230595A1 (fr) | Agent de traitement contre le cancer gastrique diffus | |
US20240207301A1 (en) | Pharmaceutical composition and anti-tumor agent for tumor having decreased function of at least one of bap1 or pbrm1 | |
CN114948951A (zh) | Fk506或其可药用衍生物和铁死亡诱导剂联合在制备治疗癌症的药物中的用途 | |
CN108358953A (zh) | 铜与咪唑并吡啶类化合物的配合物及其应用 | |
EP4378466A1 (fr) | Composition pharmaceutique et agent antitumoral pour des tumeurs présentant au moins une fonction bap1 ou pbrm1 altérée | |
TW202241415A (zh) | 通路調節劑、含其的醫藥組成物、其用途和採用其的治療方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19757867 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19757867 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |